118 related articles for article (PubMed ID: 9084795)
1. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
Staszewski S; Hill AM; Bartlett J; Eron JJ; Katlama C; Johnson J; Sawyer W; McDade H
AIDS; 1997 Mar; 11(4):477-83. PubMed ID: 9084795
[TBL] [Abstract][Full Text] [Related]
2. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
4. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Ruiz L; Romeu J; Martínez-Picado J; Schmit JC; Vandamme AM; Balagué M; Cabrera C; Puig T; Tural C; Segura A; Sirera G; De Clercq E; Clotet B
AIDS; 1996 Dec; 10(14):F61-6. PubMed ID: 8970679
[TBL] [Abstract][Full Text] [Related]
8. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
9. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
10. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
12. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
13. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.
Chancellor JV; Hill AM; Sabin CA; Simpson KN; Youle M
Pharmacoeconomics; 1997 Jul; 12(1):54-66. PubMed ID: 10169387
[TBL] [Abstract][Full Text] [Related]
14. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
15. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M
AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730
[TBL] [Abstract][Full Text] [Related]
17. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.
Eron JJ
AIDS; 1996 Dec; 10 Suppl 5():S11-9. PubMed ID: 9030391
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
Saag MS; Tebas P; Sension M; Conant M; Myers R; Chapman SK; Anderson R; Clendeninn N;
AIDS; 2001 Oct; 15(15):1971-8. PubMed ID: 11600825
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
Phillips AN; Eron JJ; Bartlett JA; Rubin M; Johnson J; Price S; Self P; Hill AM
AIDS; 1996 Jul; 10(8):859-65. PubMed ID: 8828743
[TBL] [Abstract][Full Text] [Related]
20. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Haubrich R; Thompson M; Schooley R; Lang W; Stein A; Sereni D; van der Ende ME; Antunes F; Richman D; Pagano G; Kahl L; Fetter A; Brown DJ; Clumeck N
AIDS; 1999 Dec; 13(17):2411-20. PubMed ID: 10597783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
